Kala Bio (KALA) Finished Goods (2018 - 2019)

Kala Bio (KALA) posted Finished Goods of $585000.0 for Q2 2019, down 12.95% sequentially from $672000.0 in Q1 2019.

Kala Bio (KALA) Finished Goods (2018 - 2019) Analysis & Trends

Kala Bio has reported Finished Goods for 2 years, with the latest figure at $585000.0 in Q2 2019.

Quarterly Finished Goods changed N/A year-over-year to $585000.0 in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $585000.0 (changed N/A YoY) and the FY2018 annual result came in at $388000.0, changed N/A from the prior year.
Finished Goods fell to $585000.0 in Q2 2019 per KALA's latest filing, from $672000.0 in the prior quarter.
Over five years, Finished Goods peaked at $672000.0 in Q1 2019 and troughed at $388000.0 in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.71 Bn	131.86 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.55 Bn	78.55 Bn	3.93 Bn
3	Argenx Se	65.26 Bn	60.07 Bn	1.37 Bn
4	Moderna	59.81 Bn	54.67 Bn	52.00 Mn
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.87 Bn	28.56 Bn	992.69 Mn
7	BioNTech SE	28.13 Bn	9.74 Bn	668.28 Mn
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn
9	Royalty Pharma	27.31 Bn	26.47 Bn	-
10	Kala Bio	9.96 Mn	9.96 Mn	-

Download Data